- Ridinilazole treatment resulted in a 59% reduction in recurrence compared to vancomycin
- C. difficile causes approximately 500,000 infections and 29,000 deaths in the US... read more
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced on 8/3/18 that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has... read more
BrainScope today announced its second consecutive nomination for the 2018 Annual Prix Galien USA Awards for “Best Medical Technology” product. Its flagship BrainScope One product is a multi-modal... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,